Select Page

S. RAMBOZ, A. PENNINGTON, K. COX, M. HALL, W. ARIAS, K. KAYSER, J. GUTERL, M. BANSAL, D. HAVAS, K. CIRILLO


Parkinson’s disease (PD) and synucleinophathies are neurodegenerative disorders defined by α-synuclein (α-syn) accumulation. Mutations in the α-syn gene have been demonstrated in vitro and in vivo to accelerate the aggregation and formation of α-syn fibrils, a disease marker. Presence of α-syn positive Lewy bodies were identified in neuropathological analyses of a group of Gaucher disease type I [GD] patients [Sidransky, 2005]. Further human genetic studies have also linked glucocerebrosidase (GCase) gene GBA1 mutations to PD making
this mutation the highest genetic risk factor to PD [Sidransky, 2009]. Due to the strong Robust chemically induced animal model of Gaucher disease for preclinical study clinical correlation between PD and GD diseases, animal models that demonstrate relevant and robust phenotypes [behavior, mRNA and protein profiling, IHC, ⋯] are of necessity. Genetically modified animals models carrying point mutations in GCase mimicking type 2 and type 3 have been generated targeting neuronal cells [Enquist et al. 2007; Liu et al. 1998]. In the present study, we focus on a chemically induced model consisting in daily injection of the irreversible GCase inhibitor conduritol B-epoxide (CBE) [Vardi et al., 2016). C57Bl6 mice were dosed daily via intraperitoneal injection at two different doses starting at post-natal day 8 to 22. Each pup was monitored closely and assess to motor, coordination and gait functions weekly from 3 weeks of age until study completion. Gait measures were assessed using PsychoGenics proprietary high through put gait platform, NeuroCube®. Preliminary assessment of data demonstrate progressive and CBE dose-dependent phenotypic deterioration of responses during assessments. Thus, our data demonstrate the progressive and robust phenotype of the chemically-induced GD model as an alternative to genetically modified animal models.